Salix to Acquire InKine in Gastrointestinal Merger
Business Review Editor
Abstract
Salix Pharmaceuticals acquired InKine Pharmaceutical thereby strengthening itself in the area of gastrointestinal diseases. The acquisition deal could be worth up to US$190 M to InKine.
Full Text: pdf
Add comment

This work is licensed under a Creative Commons Attribution 3.0 License.